Cigna Corporation CI

NYSE · Healthcare · Medical - Healthcare Plans

$270.90

Close on Fri, 20 Nov 2026 · market value $71.4B

What the price is betting on

Below its record

At $271, the price assumes revenue shrinks about 16% a year for five years, from $286B to about $135B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−16%
Analysts, next two years4.4%
Last 3 years15%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.7% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than CI? Check up to 5 of your stocks at once, free, no account.

0$100B$200B$300B$400B$286B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$823

Base

$925

Bull

$1,039

Today $271

  • Bear $823. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $925. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $1,039. Cash flow grows 7% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$274B$288B, on the path
  3. FY2027$230B$300B, on the path
  4. FY2028$193B$316B, on the path
  5. FY2029$161B$335B, on the path
  6. FY2030$135B$350B, on the path

Each year's revenue at −16% growth from $286B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Healthcare Plans · listed on NYSE

Revenue, FY2025
$275B
Growth, 3 years a year
15%
Cash margin
3.1%
Net debt
$23.8B
Shares, 3-year change
−15%
Dividend yield
2.3%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.